ocrelizumab
Showing 1 - 25 of 53
Ocrelizumab Effects on the Metabolome in MS
Active, not recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Baltimore, MarylandJohns Hopkins University
Jan 30, 2023
Ocrelizumab and Ofatumumab Administration in Relapsing Multiple
Completed
- Relapsing Forms of Multiple Sclerosis
- Ocrelizumab
- Ofatumumab
-
Lutherville, Maryland
- +1 more
Oct 19, 2022
Symptom Burden in Patients Treated With Ocrelizumab for Multiple
Active, not recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Wellesley, Massachusetts
- +1 more
Oct 14, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in Amsterdam (Ocrelizumab)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Ocrelizumab
-
Amsterdam, Noord-Holland, NetherlandsAmsterdam UMC, location VU
Apr 21, 2022
Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo for Ocrelizumab)
Recruiting
- Multiple Sclerosis
- Ocrelizumab
- Placebo for Ocrelizumab
-
New Haven, Connecticut
- +9 more
Jan 17, 2023
Multiple Sclerosis Trial in Moskva, Saint-Petersburg (Ocrelizumab)
Recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Moskva, Moskovskaja Oblast, Russian Federation
- +1 more
Aug 2, 2022
Ocrelizumab in Breastmilk
Active, not recruiting
- Multiple Sclerosis
- Clinically Isolated Syndrome
- Ocrelizumab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 21, 2022
Physiological and Cognitive Changes in Multiple Sclerosis
Completed
- Multiple Sclerosis
- Ocrelizumab
-
Buffalo, New YorkJacobs Institute
Mar 9, 2022
Multiple Sclerosis, Clinically Isolated Syndrome Trial in Worldwide (Ocrelizumab)
Recruiting
- Multiple Sclerosis
- Clinically Isolated Syndrome
- Ocrelizumab
-
San Francisco, California
- +5 more
Aug 2, 2022
Mechanistic Study of Ocrevus
Recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Ann Arbor, MichiganUniversity of Michigan
Jul 27, 2022
Multiple Sclerosis Trial in France (Ocrelizumab)
Recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Amiens, France
- +14 more
Jul 12, 2022
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome Trial in San Francisco (Ocrelizumab)
Recruiting
- Relapsing Multiple Sclerosis
- Clinically Isolated Syndrome
- Ocrelizumab
-
San Francisco, CaliforniaUniversity of California San Francisco
Apr 28, 2022
Multiple Sclerosis, Clinically Isolated Syndrome Trial in Worldwide (Ocrelizumab)
Recruiting
- Multiple Sclerosis
- Clinically Isolated Syndrome
- Ocrelizumab
-
San Francisco, California
- +9 more
Aug 2, 2022
Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,
Terminated
- Relapsing-Remitting Multiple Sclerosis
- Autologous Hematopoietic Stem Cell Transplantation
- +2 more
-
Hamburg, Germany
- +1 more
Mar 1, 2022
Ocrelizumab Access by Socio-Economic Status
Not yet recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Boston, MassachusettsBrigham and Women's Hospital
Nov 22, 2021
Radiologically Isolated Syndrome, Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo)
Recruiting
- Radiologically Isolated Syndrome
- Multiple Sclerosis
- Ocrelizumab
- Placebo
-
Los Angeles, California
- +15 more
Jan 30, 2023
Autoimmune Encephalitis Trial in Dallas (Ocrelizumab, Saline)
Terminated
- Autoimmune Encephalitis
- Ocrelizumab
- Saline
-
Dallas, TexasUT Southwestern Medical Center
Sep 21, 2021
Relapsing Remitting Multiple Sclerosis Trial in Norway (Rituximab, Ocrelizumab)
Recruiting
- Relapsing Remitting Multiple Sclerosis
- Rituximab
- Ocrelizumab
-
Bergen, Norway
- +10 more
Mar 18, 2022
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial
Recruiting
- Relapsing Remitting Multiple Sclerosis
- +2 more
- Rituximab
- +4 more
-
Glostrup, Copenhagen, Denmark
- +11 more
May 3, 2022
Multiple Sclerosis Trial in Italy, Poland, United States (Ocrelizumab)
Recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Loma Linda, California
- +22 more
Jan 13, 2023
Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With
Not yet recruiting
- Multiple Sclerosis
- Ocrelizumab
-
Istanbul, Uskudar, TurkeyHealth Sciences University Istanbul Haydarpaşa Numune Training a
Aug 25, 2021
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive Trial in Worldwide (Ocrelizumab, Lumbar Puncture,
Active, not recruiting
- Relapsing Multiple Sclerorsis
- Multiple Sclerosis, Primary Progressive
- Ocrelizumab
- +3 more
-
Palo Alto, California
- +16 more
Jul 26, 2022
Multiple Sclerosis Trial in Aurora (Ocrelizumab, Rituximab)
Completed
- Multiple Sclerosis
- Ocrelizumab
- Rituximab
-
Aurora, ColoradoUniversity of Colorado Hospital
Jul 1, 2021
Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
- Multiple Sclerosis
- Diroximel Fumarate
- +8 more
-
Eden Prairie, MinnesotaOptumInsight
Jan 9, 2023